GLP-1 drugs to carry warning about rare vision-loss side effect, FDA says

The U.S. Food and Drug Administration (FDA) has mandated that manufacturers of popular weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound add warning labels about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to sudden, permanent vision loss. This decision follows research indicating that patients using these drugs are at an increased risk of developing NAION compared to those not taking the medication. Warning signs may include painless vision loss in one eye upon waking, blurred vision, and missing patches of sight. The FDA’s action aims to ensure that both patients and healthcare providers are aware of this potential side effect.